Oversulfated Chondroitin Sulfate Inhibits the Complement Classical Pathway by Potentiating C1 Inhibitor

• Zhao-Hua Zhou,

  Affiliation Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Mohsen Rajabi,

  Affiliation Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Trina Chen,

  Affiliation Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Elena Karnaukhova,

  Affiliation Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Steven Kozlowski

  * E-mail: Steven.Kozlowski@fda.hhs.gov

  Affiliation Division of Monoclonal Antibodies, Office of Biotechnology Products, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯